TriangleNCT00471536 · OUTCOME
Duration of Response
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- From the time an objective response is first noted to be either a CR or PR to the date progression is documented, assessed up to 1 year
What was measured
The distribution of response durations will be estimated using the Kaplan-Meier method.
Analysis population: There were no responses.
Groups in this outcome
Treatment (Enzyme Inhibitor Therapy)
Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- The distribution of response durations will be estimated using the Kaplan-Meier method.
- groups
- description
- Patients receive oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- population Description
- There were no responses.
- reporting Status
- POSTED
- time Frame
- From the time an objective response is first noted to be either a CR or PR to the date progression is documented, assessed up to 1 year
- title
- Duration of Response
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice